Bernhard Hampl, Ph.D. joined Great Point Partners’ CEO Advisory Board in 2011. He was previously the Co-Chairman of the Board of Directors of the GPP II portfolio company, Softbox and the Co-Chairman of the Board of Directors of GPP I portfolio company, Cytovance Biologics.
Dr. Hampl is President of BKH Pharma-Services and currently Chairman of Solaris Pharma Corp., a Generic manufacturer of off-patent semi-solid drugs. Previously, Dr. Hampl was Executive Chairman of the Board of APP / Fresenius Kabi U.S. from 2009 to 2012 and served on the Boards of API manufacturers Chemwerth and Cambrex, as well as Press Ganey, the US largest healthcare experience company and SiO2, a material science company. Prior to that, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until its acquisition by Novartis in a $2.8 billion deal, at which time he became the CEO of the Sandoz US-division of Novartis from 2005 to 2008. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million. He is also a minority investor in several start-up pharmaceutical companies.
Dr. Hampl earned a Ph.D. in pharmaceutical chemistry from the Ludwig Maximilian University of Munich, Germany, School of Chemistry and Pharmacy.
- Sandoz US-division of Novartis – biosimilar, biologic and generic pharmaceuticals
- Eon Labs – specialty pharmaceuticals